Abstract:Objective: We compared Chinese and American pharmaceutical companies' corporate social responsibility (CSR) reports to determine their differences and to analyze the possible reasons for them. Methods: We took as a model the top 500 pharmaceutical companies from Torreya's (a global investment bank) list of the 1,000 most valuable pharmaceutical companies in the world. We then collected the 2020 corporate social responsibility reports of 97 Chinese and 94 American pharmaceutical companies. These reports were analyzed using software such as ROST Content Mining 6.0 and Gephi 0.92. Results: We formed a high-frequency word list, a semantic network diagram, and a high-frequency word centrality scale for the Chinese and American pharmaceutical corporate social responsibility reports. The Chinese pharmaceutical companies' corporate social responsibility reports formed a layout of "double centers and double themes," and the text paid more attention to the disclosure of environmental protection information. The American pharmaceutical companies formed a report presentation form of "three centers and two themes," focusing on corporate social responsibility information disclosures from the perspective of humanistic care. Discussion: The differences in between Chinese and American pharmaceutical companies' corporate social responsibility reports may be due to different corporate development strategies, regulatory requirements, social demands, and the concept of "corporate citizenship." This study makes recommendations for Chinese pharmaceutical companies to better fulfill their CSR at three levels: policy-making, company management, and society.

Research on Social Responsibility Information Disclosure and Performance of Pharmaceutical Companies: Based on the Perspective of Institutional Investor Governance

Does CSR Information Disclosure Improve Investment Efficiency? The Moderating Role of Analyst Attention

Corporate governance, social responsibility information disclosure, and enterprise value in China

An Empirical Study on the Impact of Social Responsibility on Financial Performance of Pharmaceutical Manufacturing Enterprises

The Status Quo Of And The Reflections On The Information Disclosure Of Listed Companies In China

Research on the Relationship between Corporate Social Responsibility and Financial Performance of Chemical Companies

Corporate Social Responsibility Information Disclosure and Innovation Sustainability: Evidence from China

The Relationship Between Heterogeneous Institutional Investors' Shareholdings and Corporate ESG Performance: Evidence From China

Incentives for Corporate Environmental Information Disclosure in China: Public Media Pressure, Local Government Supervision and Interactive Effects

The impact of the quality of environmental information disclosure on financial performance: the moderating effect of internal and external stakeholders

Corporate Social Responsibility, Analyst Focus and Firm Performance

Corporate Social Responsibility Disclosure Quality and Firms' Investment Efficiency: Evidence from Chinese Listed Companies

Information interactions on social media platforms and the quality of corporate social responsibility disclosure: Evidence from Chinese listed firms

Comparation of differences in the performance of corporate social responsibility between Chinese and American pharmaceutical enterprises—based on corporate social responsibility report

Research on Information Disclosure Quality of Corporate Social Responsibility from Corporate Governance Perspective

Corporate Social Responsibility Disclosure and Catering to Investor Sentiment in China

Analysis of the Influence of Accounting Information Disclosure on Investors' Decision-Making in Corporate Social Responsibility Report

ESG and performance in public health-care companies: the role of disclosure and director liability

Research on Environmental Accounting Information Disclosure Problems of Shanghai A Shares Pharmaceutical Enterprise